Advanced method for evaluation of gastric cancer risk by serum markers: Determination of true low-risk subjects for gastric neoplasm

Helicobacter

Volumn 19, Issue 1, 2014, Pages 1-8

  Boda, Tomoyuki ^a   Ito, Masanori ^a   Yoshihara, Masaharu ^a   Kitamura, Yoko ^a   Matsuo, Taiji ^b   Oka, Shiro ^b   Tanaka, Shinji ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gastric cancer; Gastrin; Helicobacter pylori; Pepsinogen; Risk management

Indexed keywords

GASTRIN; PEPSINOGEN I; PEPSINOGEN II; TUMOR MARKER;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; BACTERIAL CLEARANCE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; EARLY CANCER; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MIDDLE AGED; PATIENT CODING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STOMACH ADENOMA; STOMACH ATROPHY; STOMACH CANCER; VERY ELDERLY;

GASTRIC CANCER; GASTRIN; HELICOBACTER PYLORI; PEPSINOGEN; RISK MANAGEMENT;

ADULT; AGED; AGED, 80 AND OVER; ATROPHY; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MICROSCOPY; MIDDLE AGED; PEPSINOGEN A; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890861231     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12101     Document Type: Article

References (29)

1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer Incidence in Five Continents. Vol. IX. Lyon: IARC Scientific Publication No 160; 2009.
2. Kayama T, Wakao F, Sobue T, Katanoda K, Tsukuma H, Mikami H, Kitai A. Number of Deaths, by Cancer Site 2010. In: Kayama T, ed. Cancer statistics in Japan 2011. Tokyo: Foundation for Promotion of Cancer Research 2011, 2011;12.
3. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
4. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
5. Forman D, Coleman M, Backer GD, Elder J, Moller H. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359-62.
6. Asaka M, Kimura T, Kato M, Kudo M, Miki K, Ogoshi K, Kato T, Tatsutza M, Graham DY. Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer 1994;73:2691-4.
7. Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low Prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter 2011;16:415-9.
8. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
9. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43.
10. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003;98:735-9.
11. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005;54:764-8.
12. Mizuno S, Miki I, Ishida T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci 2010;55:3132-7.
13. Fukayama M, Ushiku T. Epstein-Barr virus-associated gastric carcinoma. Pathol Res Pract 2011;207:529-37.
14. Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010;47:436-44.
15. Karlsson FA, Burman P, Lööf L, Mårdh S. Major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid-producing H+, K+-adenosine triphosphatase of the stomach. J Clin Invest 1988;81:475-9.
16. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the updated Sydney system. Am J Surg Pathol 1996;20:1161-81.
17. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;1:87-97.
18. Japanese gastric cancer association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-12.
19. Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y, Komoto K, Tanaka S, Kajiyama G. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 1998;93:1090-6.
20. Ueda H, Ito M, Eguchi H, Tanaka S, Yoshihara M, Haruma K, Hatakeyama M, Chayama K. Development of a novel method to detect Helicobacter pylori cagA genotype from paraffin-embedded materials: comparison between patients with duodenal ulcer and gastric cancer in young Japanese. Digestion 2006;73:47-53.
21. Yanaoka K, Oka M, Yoshimura N, et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 2008;123:917-26.
22. Wagner S, Haruma K, Gladziwa U, Soudah B, Gebel M, Bleck J, Schmidt H, Manns M. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 1994;89:1211-8.
23. Matsuo T, Ito M, Tatsugami M, Boda T, Takata S, Tanaka S, Chayama K. Gastric cancer development after Helicobacter pylori eradication therapy: a new form of gastric neoplasia. Digestion 2012;85:61-7.
24. Inoue K, Fujisawa T, Haruma K. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int J Biol Markers 2010;25:207-12.
25. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-"ABC method". Proc Jpn Acad Ser B Phys Biol Sci 2011;87:405-14.
26. Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008;17:838-45.
27. Mossi S, Meyer-Wyss B, Renner EL, Merki HS, Gamboni G, Beglinger C. Influence of Helicobacter pylori, sex, and age on serum gastrin and pepsinogen concentrations in subjects without symptoms and patients with duodenal ulcers. Gut 1993;34:752-6.
28. Kawaguchi H, Haruma K, Komoto K, Yoshihara M, Sumii K, Kajiyama G. Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am J Gastroenterol 1996;91:959-62.
29. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.